drugset / Trial / NCT05694416
Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma
RandomizedParallel-groupSingle-blindTreatment
Summary
Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. The aim of this study is to compare the effect of Etoposide plus Cisplatin and Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2024-03-01
- Completion
- 2025-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |